Posts by Thomas H. Dohlman, MD
-
Perioperative Bevacizumab May Be Beneficial in High-Risk Corneal Transplantation
Thomas H. Dohlman, MD, and colleagues found that an anti-angiogenic monoclonal antibody may be protective in patients undergoing corneal transplantation who are at high risk of graft failure because of corneal neovascularization.
Biography
Dr. Dohlman is a full-time member of the Cornea and Refractive Surgery Service at Mass Eye and Ear who specializes in the medical and surgical management of corneal and external diseases.
Dr. Dohlman earned his Bachelor of Science degree from MIT and MD from the University of Massachusetts Medical School. He then completed a Postdoctoral Research Fellowship in Transplantation and Ocular Immunology at the Schepens Eye Research Institute of Mass Eye and Ear. He went on to complete his residency training in ophthalmology at New York Presbyterian/Weill Cornell Medical College, after which he returned to Mass Eye and Ear for further subspecialty training as an Advanced Two-Year Combined Clinical and Research Fellow in Cornea, Refractive Surgery, and External Disease.
Following fellowship, Dr. Dohlman joined the faculty at Harvard Medical School and Mass Eye and Ear as an NIH-funded clinician scientist, caring for patients and conducting basic science and clinical research in the areas of corneal immunology and inflammation, corneal fibrosis/scarring and ocular surface disease.
Mass Eye and Ear/Mass General Ophthalmology
An international center for ophthalmology treatment and research, Mass Eye and Ear/Massachusetts General Hospital is the primary teaching hospital of Harvard Medical School’s Department of Ophthalmology, and is consistently recognized as one of the nation’s top hospitals for eye care. Led by Chief and Chair Joan W. Miller, MD, the department provides seamless access to the most innovative care available anywhere in the world.
